“We like pharma as a sector because we think there is earning resilience in the sector. And more importantly, the sector is coming out of two years or three years of underperformance and business challenges. And now a lot of those headwinds which the sector faced has turned into tailwinds.”
| Subscribe To Our Free Newsletter |
